Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.

导出 OA

翻译打印收藏纠错

作者： Vatche,Tchekmedyian ^[1] ; Lara,Dunn ^[1] ; Eric,Sherman ^[2] ; Shrujal S,Baxi ^[1] ; Ravinder K,Grewal ^[2] ; Steven M,Larson ^[1] ; Keith S,Pentlow ^[3] ; Sofia,Haque ^[3] ; R Michael,Tuttle ^[4] ; Mona M,Sabra ^[3] ; Stephanie,Fish ^[1] ; Laura,Boucai ^[2] ; Jamie,Walters ^[1] ; Ronald A,Ghossein ^[2] ; Venkatraman E,Seshan ^[1] ; Jeffrey A,Knauf ^[2] ; David G,Pfister ^[1] ; James A,Fagin ^[2] ; Alan L,Ho ^[1]

作者单位： Department of Medicine, New York, New York, USA. ^[1] Department of Medicine, Weill Cornell Medical College, New York, New York, USA. ^[2] Department of Radiology, New York, New York, USA. ^[3] Department of Medical Physics, New York, New York, USA. ^[4] Department of Pathology, New York, New York, USA. ^[5] Department of Epidemiology and Biostatistics; New York, New York, USA. ^[6] Department of Human Oncology and Pathogenesis Program; Memorial Sloan Kettering Cancer Center, New York, New York, USA. ^[7]

关键词 BRAF mutant CDX-3379 radioiodine refractory thyroid cancer redifferentiation vemurafenib

主题词抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);人类(Humans);碘放射性同位素(Iodine Radioisotopes);突变(Mutation);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);甲状腺肿瘤(Thyroid Neoplasms)

DOI 10.1089/thy.2021.0565

PMID 35045748

发布时间 2023-03-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交